SYN logo

Synthetic Biologics (SYN) Stock

Profile

Full Name:

Synthetic Biologics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

12 February 1993

Indexes:

Not included

Description:

Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat gastrointestinal (GI) diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase II clinical trial designed to degrade commonly used intravenous beta-lactam antibiotics in GI tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. The company also develops clinical stage products, such as SYN-006 and SYN-007 for the prevention of CDI, overgrowth of pathogenic organisms, and AMR; and SYN-005 for the prevention and treatment of pertussis. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company is headquartered in Rockville, Maryland.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Nov 03, 2022

Recent annual earnings:

Mar 16, 2022
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

July 25, 2022

Analyst ratings

Recent major analysts updates

No data about analysts updates

Screeners with SYN included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Similar stocks

Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody
SYN
globenewswire.com14 January 2025

ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy in patients with advanced NSCLC in China

FAQ

  • What is the primary business of Synthetic Biologics?
  • What is the ticker symbol for Synthetic Biologics?
  • Does Synthetic Biologics pay dividends?
  • What sector is Synthetic Biologics in?
  • What industry is Synthetic Biologics in?
  • What country is Synthetic Biologics based in?
  • When did Synthetic Biologics go public?
  • Is Synthetic Biologics in the S&P 500?
  • Is Synthetic Biologics in the NASDAQ 100?
  • Is Synthetic Biologics in the Dow Jones?
  • When was Synthetic Biologics's last earnings report?
  • When does Synthetic Biologics report earnings?

What is the primary business of Synthetic Biologics?

Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat gastrointestinal (GI) diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase II clinical trial designed to degrade commonly used intravenous beta-lactam antibiotics in GI tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. The company also develops clinical stage products, such as SYN-006 and SYN-007 for the prevention of CDI, overgrowth of pathogenic organisms, and AMR; and SYN-005 for the prevention and treatment of pertussis. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company is headquartered in Rockville, Maryland.

What is the ticker symbol for Synthetic Biologics?

The ticker symbol for Synthetic Biologics is NYSE American:SYN

Does Synthetic Biologics pay dividends?

No, Synthetic Biologics does not pay dividends

What sector is Synthetic Biologics in?

Synthetic Biologics is in the Healthcare sector

What industry is Synthetic Biologics in?

Synthetic Biologics is in the Biotechnology industry

What country is Synthetic Biologics based in?

Synthetic Biologics is headquartered in United States

When did Synthetic Biologics go public?

Synthetic Biologics's initial public offering (IPO) was on 12 February 1993

Is Synthetic Biologics in the S&P 500?

No, Synthetic Biologics is not included in the S&P 500 index

Is Synthetic Biologics in the NASDAQ 100?

No, Synthetic Biologics is not included in the NASDAQ 100 index

Is Synthetic Biologics in the Dow Jones?

No, Synthetic Biologics is not included in the Dow Jones index

When was Synthetic Biologics's last earnings report?

Synthetic Biologics's most recent earnings report was on 3 November 2022

When does Synthetic Biologics report earnings?

The date for Synthetic Biologics's next earnings report has not been announced yet